Theravance Biopharma, Inc. (TBPH)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $17.03
- As of
Kresmion compiles this page from TBPH's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Theravance Biopharma, Inc. (TBPH): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-23.
See the full TBPH dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TBPH on one page. Preview it with sample data, then open it live with a free account.
Preview the TBPH dossierActive events for TBPH
- mediumEarnings below estimates
Q2-2026: Missed consensus by 92.2%, EPS $0.004 vs $0.051 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 73% of TBPH (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +337% to TBPH (2026Q2)
- medium13F: new position
RENAISSANCE TECHNOLOGIES LLC new position in TBPH
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +134% to TBPH (2026Q1)
FREE, NO ACCOUNT
Every event on TBPH, as it fires
You are seeing 5 of 9 events recorded on TBPH since 2026-06-03.
The five above landed across 3 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TBPH (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP G8807B106 · 2026Q2 | $20.8M | 0.02% | , |
| D. E. Shaw & Co., Inc.CUSIP G8807B106 · 2026Q2 | $20.2M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP G8807B106 · 2026Q2 | $8.6M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP G8807B106 · 2026Q2 | $2.6M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP G8807B106 · 2026Q2 | $2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TBPH
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TBPH against its peers
TBPH's operating margin of -3.4% ranks in the 61st percentile of 8 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2025-12-31.
| Metric | TBPH | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 107M USD | 209M USD | 39 | 8 |
| Operating margin | -3.4% | -26.9% | 61 | 8 |
| Net margin | 98.5% | -23.2% | 83 | 8 |
| Return on equity | 35.7% | -43.0% | 90 | 14 |
Peers (17): MGTX, RIGL, CRVS, CGEM, VSTM, KURA, GLUE, JBIO, PHAR, AVBP, SVRA, MLTX, ARDX, SGP, ORIC, MNKD, HELP. Left out: IVA (period gap), AKTS (no annual filing), OBX (no annual filing), SLBT (no annual filing), ODTX (no annual filing), APMD (no annual filing), LTGO (no annual filing), CTY (no annual filing). Fiscal periods ending between 2025-03-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (TBPH: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow TBPH on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to TBPH for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.